$PTCT
PTC THERAPEUTICS, INC.

2023 Q2 Form 10-Q Financial Statement

#000107008123000028 Filed on April 27, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $213.8M $220.4M
YoY Change 29.17% 48.17%
Cost Of Revenue $12.73M $14.14M
YoY Change 32.08% 39.56%
Gross Profit $201.1M $206.2M
YoY Change 28.99% 48.8%
Gross Profit Margin 94.05% 93.58%
Selling, General & Admin $88.45M $86.91M
YoY Change 10.71% 18.62%
% of Gross Profit 43.99% 42.14%
Research & Development $185.9M $195.1M
YoY Change 18.19% 39.3%
% of Gross Profit 92.44% 94.61%
Depreciation & Amortization $51.00M $42.83M
YoY Change 74.79% 62.75%
% of Gross Profit 25.37% 20.76%
Operating Expenses $192.8M $338.0M
YoY Change -25.23% 43.67%
Operating Profit $8.257M -$117.6M
YoY Change -108.94% 35.94%
Interest Expense -$32.12M -$27.33M
YoY Change 46.14% 16.23%
% of Operating Profit -388.94%
Other Income/Expense, Net $4.179M $9.956M
YoY Change -112.16% -183.98%
Pretax Income -$237.5M -$135.0M
YoY Change 59.71% 10.75%
Income Tax -$38.60M $3.969M
% Of Pretax Income
Net Earnings -$198.9M -$139.0M
YoY Change 30.77% 9.65%
Net Earnings / Revenue -93.02% -63.05%
Basic Earnings Per Share -$2.66 -$1.88
Diluted Earnings Per Share -$2.66 -$1.88
COMMON SHARES
Basic Shares Outstanding 74.19M 73.82M
Diluted Shares Outstanding 74.73M 73.73M

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $337.9M $286.3M
YoY Change -33.15% -51.29%
Cash & Equivalents $208.4M $167.5M
Short-Term Investments $129.6M $118.8M
Other Short-Term Assets $42.23M $98.57M
YoY Change 10.59% 232.49%
Inventory $32.02M $26.65M
Prepaid Expenses
Receivables $177.5M $201.9M
Other Receivables $0.00 $0.00
Total Short-Term Assets $589.7M $613.4M
YoY Change -15.11% -20.75%
LONG-TERM ASSETS
Property, Plant & Equipment $178.8M $79.49M
YoY Change 175.47% 34.53%
Goodwill $82.30M $82.30M
YoY Change 0.0% 0.0%
Intangibles $451.6M $686.2M
YoY Change -40.59% -10.14%
Long-Term Investments
YoY Change
Other Assets $35.65M $47.88M
YoY Change -40.92% 7.85%
Total Long-Term Assets $748.4M $995.4M
YoY Change -32.54% -2.94%
TOTAL ASSETS
Total Short-Term Assets $589.7M $613.4M
Total Long-Term Assets $748.4M $995.4M
Total Assets $1.338B $1.609B
YoY Change -25.83% -10.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $97.72M $26.31M
YoY Change 327.08% 43.27%
Accrued Expenses $99.80M $82.02M
YoY Change 12.12% 3.15%
Deferred Revenue $214.0K
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $107.6M $99.73M
YoY Change -28.24% -33.39%
Total Short-Term Liabilities $476.3M $441.6M
YoY Change -16.04% -7.37%
LONG-TERM LIABILITIES
Long-Term Debt $1.251B $572.1M
YoY Change 342.91% 102.74%
Other Long-Term Liabilities $138.1M $141.0K
YoY Change -54.03% -99.95%
Total Long-Term Liabilities $1.389B $572.2M
YoY Change 391.79% 102.79%
TOTAL LIABILITIES
Total Short-Term Liabilities $476.3M $441.6M
Total Long-Term Liabilities $1.389B $572.2M
Total Liabilities $1.917B $2.066B
YoY Change -3.47% 9.32%
SHAREHOLDERS EQUITY
Retained Earnings -$2.995B -$2.796B
YoY Change 26.0% 25.68%
Common Stock $75.00K $73.00K
YoY Change 5.63% 2.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$579.3M -$457.6M
YoY Change
Total Liabilities & Shareholders Equity $1.338B $1.609B
YoY Change -25.83% -10.6%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$198.9M -$139.0M
YoY Change 30.77% 9.65%
Depreciation, Depletion And Amortization $51.00M $42.83M
YoY Change 74.79% 62.75%
Cash From Operating Activities -$14.12M -$29.49M
YoY Change -74.44% -69.72%
INVESTING ACTIVITIES
Capital Expenditures $6.245M $10.27M
YoY Change -171.78% 10.29%
Acquisitions
YoY Change
Other Investing Activities -$17.51M -$18.70M
YoY Change -121.63% -132.05%
Cash From Investing Activities -$23.75M -$28.97M
YoY Change -132.87% -159.07%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 18.46M 4.094M
YoY Change 378.11% 250.51%
NET CHANGE
Cash From Operating Activities -14.12M -29.49M
Cash From Investing Activities -23.75M -28.97M
Cash From Financing Activities 18.46M 4.094M
Net Change In Cash -19.41M -62.33M
YoY Change -193.0% 36.87%
FREE CASH FLOW
Cash From Operating Activities -$14.12M -$29.49M
Capital Expenditures $6.245M $10.27M
Free Cash Flow -$20.36M -$39.76M
YoY Change -56.24% -62.74%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 ptct Adjustments To Additional Paid In Capital Receivable From Investor
AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor
396000
CY2023Q1 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease
DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
0
CY2023Q1 us-gaap Debt Securities Trading Realized Gain Loss
DebtSecuritiesTradingRealizedGainLoss
0
CY2022Q1 us-gaap Debt Securities Trading Realized Gain Loss
DebtSecuritiesTradingRealizedGainLoss
-100000
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001070081
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3416587
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
100 Corporate Court
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
South Plainfield
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07080
CY2023Q1 dei City Area Code
CityAreaCode
908
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
222-7000
CY2023Q1 us-gaap Goodwill
Goodwill
82341000
CY2022Q4 us-gaap Goodwill
Goodwill
82341000
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2023Q1 dei Trading Symbol
TradingSymbol
PTCT
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5655000
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
74190700
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
167495000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
279834000
CY2023Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
118808000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
130871000
CY2023Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
201867000
CY2022Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
155614000
CY2023Q1 us-gaap Inventory Net
InventoryNet
26649000
CY2022Q4 us-gaap Inventory Net
InventoryNet
21808000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
98573000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
105658000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
613392000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
693785000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
79492000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
72590000
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
686205000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
705891000
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
74012034
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
73104692
CY2023Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
200000
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-35969
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
PTC Therapeutics, Inc.
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
99531000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
102430000
CY2023Q1 ptct Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
47878000
CY2022Q4 ptct Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
48582000
CY2023Q1 us-gaap Assets
Assets
1608839000
CY2022Q4 us-gaap Assets
Assets
1705619000
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
332091000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
320366000
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
214000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1351000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
9598000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
9370000
CY2023Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1857000
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
3000000
CY2023Q1 ptct Liability Sale Of Future Royalties Current
LiabilitySaleOfFutureRoyaltiesCurrent
97874000
CY2022Q4 ptct Liability Sale Of Future Royalties Current
LiabilitySaleOfFutureRoyaltiesCurrent
72149000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
441634000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
406236000
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
572091000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
571722000
CY2023Q1 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
166400000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
164000000
CY2023Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
102831000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
102834000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
100442000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
100860000
CY2023Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
17184000
CY2022Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
18675000
CY2023Q1 ptct Liability Sale Of Future Royalties Noncurrent
LiabilitySaleOfFutureRoyaltiesNoncurrent
665677000
CY2022Q4 ptct Liability Sale Of Future Royalties Noncurrent
LiabilitySaleOfFutureRoyaltiesNoncurrent
685737000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
141000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2641000
CY2023Q1 us-gaap Liabilities
Liabilities
2066400000
CY2022Q4 us-gaap Liabilities
Liabilities
2052705000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
74012034
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
73104692
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
73000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
72000
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2339886000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2305020000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1587000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4796000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2795933000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2656974000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-457561000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-347086000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1608839000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1705619000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
220382000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
148735000
CY2023Q1 ptct Costof Goodsand Service Excluding Amortization Of Intangible Assets
CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets
14144000
CY2022Q1 ptct Costof Goodsand Service Excluding Amortization Of Intangible Assets
CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets
10135000
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
39415000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
23473000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
195124000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
140078000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
86914000
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
73271000
CY2023Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
-2400000
CY2022Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
11700000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
337997000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
235257000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-117615000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-86522000
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-27331000
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-23514000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9956000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-11855000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-134990000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-121891000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3969000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4835000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-138959000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-126726000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73729284
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73729284
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71215105
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
71215105
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.88
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.88
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.78
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.78
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-138959000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-126726000
CY2023Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
54000
CY2022Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-2913000
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-6437000
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
8587000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-145342000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-121052000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-347086000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
28815000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-138959000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-6383000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-457561000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1438000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2444000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
26589000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-126726000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
5674000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-90581000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-138959000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-126726000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
42825000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
26314000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2942000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1908000
CY2023Q1 ptct Noncash Royalty Revenue Sale Of Future Royalties
NoncashRoyaltyRevenueSaleOfFutureRoyalties
13237000
CY2022Q1 ptct Noncash Royalty Revenue Sale Of Future Royalties
NoncashRoyaltyRevenueSaleOfFutureRoyalties
8113000
CY2023Q1 ptct Noncash Interest Expense Liability Related To Sale Of Future Royalties
NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties
18902000
CY2022Q1 ptct Noncash Interest Expense Liability Related To Sale Of Future Royalties
NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties
18874000
CY2023Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
2400000
CY2022Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-11700000
CY2023Q1 ptct Clearpoint Equity Investment Fvni Unrealized Gain Loss
ClearpointEquityInvestmentFvniUnrealizedGainLoss
-39000
CY2022Q1 ptct Clearpoint Equity Investment Fvni Unrealized Gain Loss
ClearpointEquityInvestmentFvniUnrealizedGainLoss
-1049000
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
59000
CY2022Q1 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-1542000
CY2023Q1 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
2166000
CY2022Q1 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-6477000
CY2022Q1 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-79000
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
85000
CY2022Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-887000
CY2023Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-4000
CY2023Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
438000
CY2022Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
464000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
28815000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
26589000
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
10057000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-2135000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4612000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-350000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-57611000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-25118000
CY2023Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
43426000
CY2022Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
28372000
CY2023Q1 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-743000
CY2022Q1 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
510000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
33524000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-30680000
CY2023Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-3988000
CY2023Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
440000
CY2022Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-3089000
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1137000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29491000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-97404000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10270000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9312000
CY2022Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
39035000
CY2023Q1 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
12500000
CY2022Q1 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
167101000
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
2196000
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
2423000
CY2023Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
33397000
CY2022Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
72134000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-28971000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
49043000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5655000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2444000
CY2023Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
182000
CY2023Q1 ptct Payment Of Finance Lease Principal
PaymentOfFinanceLeasePrincipal
1379000
CY2022Q1 ptct Payment Of Finance Lease Principal
PaymentOfFinanceLeasePrincipal
1276000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4094000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1168000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-7963000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1653000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-62331000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-45540000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
295925000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
197218000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
233594000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
151678000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
12956000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
6130000
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2215000
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1987000
CY2023Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
54000
CY2022Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-2913000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
587000
CY2023Q1 us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
19406000
CY2022Q1 us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
12589000
CY2023Q1 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
45000
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
28000
CY2023Q1 ptct Milestone Payable
MilestonePayable
32500000
CY2023Q1 ptct Number Of Products
NumberOfProducts
2
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2795900000
CY2023Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
10249000
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
440000
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates in these consolidated financial statements have been made in connection with the calculation of net product sales, royalty revenue, certain accruals related to the Company’s research and development expenses, valuation procedures for liability for sale of future royalties, valuation procedures for convertible notes, fair value of the contingent consideration, and the provision for or benefit from income taxes. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</p>
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
167495000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
279834000
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
16099000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
16091000
CY2023Q1 ptct Credit Agreement Reserve For Borrowed Funds
CreditAgreementReserveForBorrowedFunds
50000000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
233594000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
295925000
CY2022Q1 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2023Q1 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
10249000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
499000
CY2023Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
1097000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
1078000
CY2023Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
18438000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
14074000
CY2023Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
7114000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
6656000
CY2023Q1 us-gaap Inventory Net
InventoryNet
26649000
CY2022Q4 us-gaap Inventory Net
InventoryNet
21808000
CY2023Q1 us-gaap Inventory Write Down
InventoryWriteDown
100000
CY2022Q1 us-gaap Inventory Write Down
InventoryWriteDown
600000
CY2023Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
200000
CY2022Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
1400000
CY2022Q1 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease
DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
0
CY2023Q1 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease
DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
0
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
400000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
300000
CY2020Q3 ptct Assigned Royalty Payment Retained Percentage
AssignedRoyaltyPaymentRetainedPercentage
0.57067
CY2023Q1 ptct Revenue Recognition Milestone Potential Achievements
RevenueRecognitionMilestonePotentialAchievements
250000000.0
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
10186000
CY2017Q4 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023Q1 ptct Federal Tax Expense Benefit Irc Section174 Research And Development Expenses
FederalTaxExpenseBenefitIrcSection174ResearchAndDevelopmentExpenses
700000
CY2023Q1 ptct State Tax Expense Benefit Irc Section174 Research And Development Expenses
StateTaxExpenseBenefitIrcSection174ResearchAndDevelopmentExpenses
2900000
CY2023Q1 ptct Number Of Operating Leases
NumberOfOperatingLeases
2
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
3000000.0
CY2022Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
18700000
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
7100000
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
5300000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
499000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
10186000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
5473000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
4126000
CY2023Q1 us-gaap Variable Lease Cost
VariableLeaseCost
1353000
CY2022Q1 us-gaap Variable Lease Cost
VariableLeaseCost
1076000
CY2023Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
303000
CY2022Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
74000
CY2023Q1 ptct Lease Cost Excluding Finance Lease Costs
LeaseCostExcludingFinanceLeaseCosts
7129000
CY2022Q1 ptct Lease Cost Excluding Finance Lease Costs
LeaseCostExcludingFinanceLeaseCosts
5276000
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P11Y6M25D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P11Y7M9D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0863
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0861
CY2023Q1 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P9Y9M3D
CY2022Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P10Y3D
CY2023Q1 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0780
CY2022Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0780
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
3811000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
3411000
CY2023Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
1379000
CY2022Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
1276000
CY2023Q1 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
1621000
CY2022Q1 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
1724000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
587000
CY2023Q1 ptct Sales Rebates Current
SalesRebatesCurrent
94296000
CY2022Q4 ptct Sales Rebates Current
SalesRebatesCurrent
67355000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
11575000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
18465000
CY2023Q1 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
3000000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
20434000
CY2023Q1 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
3000000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
19986000
CY2023Q1 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
3000000
CY2023Q1 ptct Lessee Operating Lease Liability To Be Paid Year Four And After
LesseeOperatingLeaseLiabilityToBePaidYearFourAndAfter
193792000
CY2023Q1 ptct Finance Lease Liability To Be Paid Year Four And After
FinanceLeaseLiabilityToBePaidYearFourAndAfter
18000000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
264252000
CY2023Q1 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
27000000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
154212000
CY2023Q1 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
7959000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
110040000
CY2023Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
19041000
CY2023Q1 ptct Fair Value Assets Transfers Between Level1 Level2 And Level3 Amount
FairValueAssetsTransfersBetweenLevel1Level2AndLevel3Amount
0
CY2022Q4 ptct Fair Value Assets Transfers Between Level1 Level2 And Level3 Amount
FairValueAssetsTransfersBetweenLevel1Level2AndLevel3Amount
0
CY2023Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
10689000
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
440000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
10249000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
23104000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
5000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
499000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
22610000
CY2022Q1 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Writeoff
DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff
0
CY2023Q1 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Writeoff
DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff
0
CY2022Q1 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease
DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
0
CY2023Q1 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
32694000
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
10249000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
12424000
CY2022Q4 ptct Available For Sale Securities Debt Maturities Over One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue
10186000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
36417000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
62669000
CY2023Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
5730000
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
4712000
CY2023Q1 ptct Accrued Consulting And Contracted Research Current
AccruedConsultingAndContractedResearchCurrent
22547000
CY2022Q4 ptct Accrued Consulting And Contracted Research Current
AccruedConsultingAndContractedResearchCurrent
38882000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4216000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3093000
CY2023Q1 ptct Sales Allowance And Other Related Costs
SalesAllowanceAndOtherRelatedCosts
68136000
CY2022Q4 ptct Sales Allowance And Other Related Costs
SalesAllowanceAndOtherRelatedCosts
63787000
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14266694
CY2022Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
40546000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
26311000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
27268000
CY2023Q1 ptct Milestone Payable
MilestonePayable
32500000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
9244000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
12054000
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
332091000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
320366000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-138959000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-138959000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-126726000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-126726000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73729284
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73729284
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71215105
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
71215105
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.88
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.88
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.78
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.78
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15750292
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y6M
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
28815000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
26589000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
238400000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y4M20D
CY2020Q3 ptct Proceeds From Sale Of Future Royalties
ProceedsFromSaleOfFutureRoyalties
650000000.0
CY2020Q3 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0.110
CY2022Q4 ptct Liability Sale Of Future Royalties
LiabilitySaleOfFutureRoyalties
757886000
CY2023Q1 ptct Liability Sale Of Future Royalties Royalty Revenue Payable
LiabilitySaleOfFutureRoyaltiesRoyaltyRevenuePayable
13237000
CY2023Q1 ptct Liability Sale Of Future Royalties Interest Expense
LiabilitySaleOfFutureRoyaltiesInterestExpense
18902000
CY2023Q1 ptct Liability Sale Of Future Royalties
LiabilitySaleOfFutureRoyalties
763551000
CY2023Q1 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0.098
CY2022Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
200000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
1400000
CY2023Q1 us-gaap Contract With Customer Asset Gross
ContractWithCustomerAssetGross
0
CY2022Q4 us-gaap Contract With Customer Asset Gross
ContractWithCustomerAssetGross
0
CY2023Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1400000
CY2022Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
0
CY2023Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
200000
CY2022Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
1400000
CY2023Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
39400000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
23500000
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
118266000
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
33462000
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
9702000
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
9702000
CY2023Q1 ptct Finite Lived Intangible Assets Amortization Expense Year Four And Thereafter
FiniteLivedIntangibleAssetsAmortizationExpenseYearFourAndThereafter
61507000
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
232639000
CY2023Q1 us-gaap Indefinite Lived Intangible Assets Period Increase Decrease
IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease
0
us-gaap Goodwill Period Increase Decrease
GoodwillPeriodIncreaseDecrease
0
CY2023Q1 us-gaap Goodwill
Goodwill
82300000

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001070081-23-000028-index-headers.html Edgar Link pending
0001070081-23-000028-index.html Edgar Link pending
0001070081-23-000028.txt Edgar Link pending
0001070081-23-000028-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20230331.xsd Edgar Link pending
tmb-20230331x10q.htm Edgar Link pending
tmb-20230331xex10d1.htm Edgar Link pending
tmb-20230331xex10d2.htm Edgar Link pending
tmb-20230331xex31d1.htm Edgar Link pending
tmb-20230331xex31d2.htm Edgar Link pending
tmb-20230331xex32d1.htm Edgar Link pending
tmb-20230331xex32d2.htm Edgar Link pending
tmb-20230331_cal.xml Edgar Link unprocessable
tmb-20230331_lab.xml Edgar Link unprocessable
tmb-20230331_def.xml Edgar Link unprocessable
tmb-20230331_pre.xml Edgar Link unprocessable
tmb-20230331x10q_htm.xml Edgar Link completed